2014
DOI: 10.1007/s00430-014-0384-8
|View full text |Cite
|
Sign up to set email alerts
|

Electroporation for therapeutic DNA vaccination in patients

Abstract: a viral antigen under the control of a eukaryotic promoter an immune response to the viral antigen could be achieved [1]. Basically, the plasmid should be taken up by the cells, transported to the nucleus, start transcription and translation of the viral antigen. The antigen is then presented in both the major histocompatibility complex class I-and IIpathways, presumably by the transport of the antigen, and/ or transfected cell, by dendritic cells to a nearby lymph node. The lymph node is most likely the key s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
15
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(15 citation statements)
references
References 23 publications
0
15
0
Order By: Relevance
“…Although our study provides considerable incentive for the development of an electroporation device which can be safely administered to the cervicovaginal region in humans, we understand the potential concerns that may be raised regarding the clinical translation of intravaginal electroporation, including invasiveness and pain level 26 . In a previous study, participating patients reported pain at the vaccine injection site after electroporation.…”
Section: Discussionmentioning
confidence: 99%
“…Although our study provides considerable incentive for the development of an electroporation device which can be safely administered to the cervicovaginal region in humans, we understand the potential concerns that may be raised regarding the clinical translation of intravaginal electroporation, including invasiveness and pain level 26 . In a previous study, participating patients reported pain at the vaccine injection site after electroporation.…”
Section: Discussionmentioning
confidence: 99%
“…In general, DNA vaccines administered by needle and syringe have been poorly immunogenic, prompting the development of alternative modes of delivery including electroporation [7, 11, 12]. Electroporation has been shown to enhance antigen production and immunogenicity in a variety of animal models and is under evaluation in human phase I clinical trials.…”
Section: Discussionmentioning
confidence: 99%
“…DNA vaccines continue to raise considerable interest due to the ease of production and administration, genetic stability, no requirement for a cold chain, and activation of humoral, cell-mediated, and innate immunity. However, despite promising results in preclinical trials, the clinical application of traditional DNA vaccines has been limited due to various factors including low DNA uptake, low immunogenicity in humans and the need of repeated booster vaccinations with considerable quantities of DNA, as reviewed elsewhere [1, 4, 5]. Furthermore, traditional DNA vaccines are designed to express a single vaccine-relevant antigen in the tissues of vaccine recipient, essentially serving as a vector for transient expression of the subunit antigen vaccine.…”
Section: Dna-launched Live-attenuated Vaccines As Novel Dna Vaccinesmentioning
confidence: 99%
“…Improvement of DNA vaccination remains a fundamental goal of vaccine research. Methods to improve DNA vaccine-induced immunity include various techniques including prime-boost approach [10, 11], development of advanced vaccine delivery methods such as electroporation [4, 12-14], as well as improvements to plasmid production and plasmid vector design such as addition of plasmid-encoded innate immunity agonists [15-18]. …”
Section: Dna-launched Live-attenuated Vaccines As Novel Dna Vaccinesmentioning
confidence: 99%
See 1 more Smart Citation